Hyperion Defi (HYPD) Liabilities and Shareholders Equity (2016 - 2026)
Hyperion Defi (HYPD) posted quarterly Liabilities and Shareholders Equity of $70.1 million for Q1 2026, up 1070.9% year-over-year from $6.0 million in Q1 2025, and up 35.36% quarter-over-quarter from $51.8 million in Q4 2025.
Hyperion Defi (HYPD) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Hyperion Defi (HYPD) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $70.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 1070.9% year-over-year to $70.1 million; the TTM figure through Mar 2026 stood at $260.3 million (up 405.96% YoY), while the FY2025 annual figure was $51.8 million, up 1311.33% from the prior year.
- Liabilities and Shareholders Equity improved to $70.1 million in Q1 2026 per HYPD's latest filing, from $51.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $82.8 million in Q3 2025 and bottomed at $3.7 million in Q4 2024.
- Historically, Liabilities and Shareholders Equity has averaged $35.2 million across 5 years, with a median of $31.0 million in 2022.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 87.26% — and 2025, when it jumped 1311.33%.
- Hyperion Defi's Liabilities and Shareholders Equity stood at $31.0 million in 2022, then slipped by 7.27% to $28.8 million in 2023, then plunged by 87.26% to $3.7 million in 2024, then surged by 1311.33% to $51.8 million in 2025, then soared by 35.36% to $70.1 million in 2026.
- Business Quant data shows HYPD's Liabilities and Shareholders Equity at $70.1 million in Q1 2026, $51.8 million in Q4 2025, and $82.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Hyperion Defi | 44.93 Mn | 35.29 Mn | 357,693.00 | 113.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.14 Mn |
| Mar 31, 2026 | 70.07 Mn |
| Dec 31, 2025 | 51.76 Mn |
| Sep 30, 2025 | 82.79 Mn |
| Jun 30, 2025 | 55.66 Mn |
| Mar 31, 2025 | 5.98 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 22.80 Mn |
| Jun 30, 2024 | 18.99 Mn |
| Mar 31, 2024 | 26.18 Mn |
| Dec 31, 2023 | 28.78 Mn |
| Sep 30, 2023 | 34.87 Mn |
| Jun 30, 2023 | 29.35 Mn |
| Mar 31, 2023 | 29.31 Mn |
| Dec 31, 2022 | 31.04 Mn |
| Sep 30, 2022 | 31.41 Mn |
| Jun 30, 2022 | 35.61 Mn |
| Mar 31, 2022 | 40.19 Mn |
| Dec 31, 2021 | 31.66 Mn |
| Sep 30, 2021 | 24.99 Mn |